Compare SpaceX (SPCX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SpaceX vs Twist Bioscience Corp — how do they compare? SpaceX trades at $147 (market cap $2.02T), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: SpaceX is far larger — about 239.9× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.
| SPCX | TWST | |
|---|---|---|
Market Cap | $2.02T | $8.42B |
Sector | Technology | Health |
52-Week High | $202.09 | $153.10 |
52-Week Low | $108.27 | $24.16 |
Enterprise Value | $1.96T | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCX trades at $153.47, up 3.73% today, with strong analyst support (90% buy ratings) and a $227.22 consensus price target suggesting 48% upside. Despite negative profitability metrics, the company shows robust revenue growth and significant cash flow generation. Technical indicators show a bullish trend with key support at $147 and resistance at $157. Recent news highlights insider share unlocks creating temporary selling pressure but strong institutional interest.
The outlook remains positive given SpaceX's innovation pipeline and market leadership, though investors face risks from high valuation multiples, ongoing losses, and competitive pressures. The stock's premium valuation requires continued execution on growth targets to justify current levels.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
